Association of Chronic Acid Suppression and Social Determinants of Health with COVID-19 Infection

Competing Interest Statement

BSB has received consulting fees from Bristol Myers Squibb, Pfizer, and Takeda, unrelated to current research. VAR has received support from Janssen Inc. for research unrelated this work. AJB is a co-founder and consultant to Personalis and NuMedii; consultant to Samsung, Mango Tree Corporation, and in the recent past, 10x Genomics, Helix, Pathway Genomics, and Verinata (Illumina); has served on paid advisory panels or boards for Geisinger Health, Regenstrief Institute, Gerson Lehman Group, AlphaSights, Covance, Novartis, Genentech, and Merck, and Roche; is a shareholder in Personalis and NuMedii; is a minor shareholder in Apple, Facebook, Alphabet (Google), Microsoft, Amazon, Snap, 10x Genomics, Illumina, CVS, Nuna Health, Assay Depot, Vet24seven, Regeneron, Sanofi, Royalty Pharma, AstraZeneca, Moderna, Biogen, Paraxel, and Sutro, and several other non-health related companies and mutual funds; and has received honoraria and travel reimbursement for invited talks from Johnson and Johnson, Roche, Genentech, Pfizer, Merck, Lilly, Takeda, Varian, Mars, Siemens, Optum, Abbott, Celgene, AstraZeneca, AbbVie, Westat, and many academic institutions, medical or disease specific foundations and associations, and health systems. AJB receives royalty payments through Stanford University, for several patents and other disclosures licensed to NuMedii and Personalis. The research of AJB has been funded by NIH, Northrup Grumman (as the prime on an NIH contract), Genentech, Johnson and Johnson, FDA, Robert Wood Johnson Foundation, Leon Lowenstein Foundation, Intervalien Foundation, Priscilla Chan and Mark Zuckerberg, the Barbara and Gerson Bakar Foundation, and in the recent past, the March of Dimes, Juvenile Diabetes Research Foundation, California Governors Office of Planning and Research, California Institute for Regenerative Medicine, LOreal, and Progenity. All other authors have nothing to disclose relevant to the manuscript. The disclosures had no involvement in the design, collection, analysis, interpretation and decision to publish.

Funding Statement

This study was supported by funding from the UCSF Bakar Computational Health Science Institute and the National Center for Advancing Traanslational Sciences of the NIH, grant number UL1TR001872 (UCSF), UL1TR001881 (UCLA), and UL1TR001442 (UCSD). UCLA effort was supported by the Barbara and Joel Marcus UCLA GI Fellowship Research Seed Grant Program. BZ is supported by NIH/NIDDK, grant number T32DK007007-45. NN is supported by NIH/NIDDK, grant number T32DK007202. BSB is supported by NIH/NIDDK, grant number K23DK123406. VAR was supported by NIH/National Center for Advancing Translational Sciences, grant number TL1TR001871.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

UCSF IRB, UCLA IRB, UCSD IRB

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes